Khang & Khang LLP announces that it is investigating claims of potential
misrepresentations by Zosano Pharma Corporation (“Zosano” or the
“Company”) (Nasdaq: ZSAN).
The investigation focuses on whether the Company and its officers
violated securities laws by issuing misleading information to investors.
If you purchased shares of Zosano during the Class Period, please
contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman
Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by
e-mail at joon@khanglaw.com.
There has been no class certification in this case. Until certification
occurs, you are not represented by an attorney. You may choose to take
no action and remain a passive class member.
The investigation will focus on whether the Company’s filings with the
SEC concerning its January 2015 Initial Public Offering were misleading.
The Company offered more than 6,500,000 shares of its common stock at
$11.00 per share in connection with its IPO.
If you wish to learn more about this lawsuit, or if you have any
questions concerning this notice or your rights, please contact Joon M.
Khang, a prominent litigator for almost two decades, by telephone: (949)
419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160209006353/en/
Copyright Business Wire 2016